Literature DB >> 9466086

A risk-benefit assessment of aprotinin in cardiac surgical procedures.

W B Dobkowski1, J M Murkin.   

Abstract

Aprotinin, a naturally occurring serine protease inhibitor, has found widespread application during cardiac surgical procedures as a consequence of its ability to decrease blood loss and transfusion requirements. While its efficacy in a variety of clinical situations associated with increased risk of blood loss has been well established, at the same time, various complications including anaphylaxis, renal insufficiency, graft closure and arterial thromboses have been reported in association with aprotinin administration. In order to more fully evaluate the risks and benefits associated with aprotinin usage, this review first of all examines the hazards associated with transfusion of blood and blood products. Consideration is then given to various alternatives to allogeneic transfusion, including autologous predonation, acute normovolemic hemodilution, perioperative cell salvage and intraoperative plasma sequestration. A critique of other available pharmacological therapies, specifically desmopressin, aminocaproic acid and tranexamic acid, reviewing their modes of action, efficacy and associated complications, is then made. The role of aprotinin in cardiac surgery is then discussed and its pharmacology, including consideration of its antifibrinolytic, platelet preserving and anti-inflammatory effects is reviewed. Finally, an analysis of potential complications associated with aprotinin administration is undertaken. Issues involving its influence on specific measures of anticoagulation, namely partial thromboplastin time and activated clotting time, and issues relating to graft patency, hypothermic circulatory arrest, renal function, and allergic reactions are analysed and interpreted. In summary, this review concludes that most of the risks associated with aprotinin administration primarily involve inadequate anticoagulation and those of developing an allergic reaction, particularly upon aproptinin re-exposure. The benefits of aproptinin to decrease blood loss and transfusion requirements are confirmed, and there is evidence pointing to the intriguing possibility of a potential salutary effect on perioperative central nervous system complications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466086     DOI: 10.2165/00002018-199818010-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  144 in total

1.  A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery.

Authors:  T Hackmann; R D Gascoyne; S C Naiman; G H Growe; L D Burchill; W R Jamieson; S B Sheps; M T Schechter; G E Townsend
Journal:  N Engl J Med       Date:  1989-11-23       Impact factor: 91.245

2.  Coagulopathy after reinfusion of autologous scavenged red blood cells.

Authors:  D J Murray; K Gress; S L Weinstein
Journal:  Anesth Analg       Date:  1992-07       Impact factor: 5.108

3.  Immunological studies on patients who received aprotinin therapy.

Authors:  Y Yanagihara; T Shida
Journal:  Arerugi       Date:  1985-09

4.  Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy.

Authors:  M Lass; A Welz; M Kochs; G Mayer; M Schwandt; A Hannekum
Journal:  Eur J Cardiothorac Surg       Date:  1995       Impact factor: 4.191

5.  The effect of aprotinin (a serine protease inhibitor) on renal function and renin release.

Authors:  S Seto; V Kher; A G Scicli; W H Beierwaltes; O A Carretero
Journal:  Hypertension       Date:  1983 Nov-Dec       Impact factor: 10.190

6.  Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass.

Authors:  D D Frankville; G B Harper; C L Lake; R A Johns
Journal:  Anesthesiology       Date:  1991-06       Impact factor: 7.892

7.  High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery.

Authors:  M Janssens; J Joris; J L David; R Lemaire; M Lamy
Journal:  Anesthesiology       Date:  1994-01       Impact factor: 7.892

8.  Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost.

Authors:  P L Baele; J Ruiz-Gomez; C Londot; M Sauvage; M J Van Dyck; A Robert
Journal:  Acta Anaesthesiol Belg       Date:  1992

9.  The declining risk of post-transfusion hepatitis C virus infection.

Authors:  J G Donahue; A Muñoz; P M Ness; D E Brown; D H Yawn; H A McAllister; B A Reitz; K E Nelson
Journal:  N Engl J Med       Date:  1992-08-06       Impact factor: 91.245

10.  Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients.

Authors:  G Benoni; H Fredin
Journal:  J Bone Joint Surg Br       Date:  1996-05
View more
  4 in total

Review 1.  Fibrin sealant: a review of its use in surgery and endoscopy.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 2.  Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.

Authors:  D C Peters; S Noble
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

3.  The fibrinolytic system attenuates vascular tone: effects of tissue plasminogen activator (tPA) and aminocaproic acid on renal microcirculation.

Authors:  Samuel N Heyman; Zohair Hanna; Taher Nassar; Ahuva Shina; Sa'ed Akkawi; Marina Goldfarb; Seymour Rosen; Abd-Al Roof Higazi
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

Review 4.  A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.

Authors:  Ian S Fraser; Robert J Porte; Peter A Kouides; Andrea S Lukes
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.